Orforglipron
ATTAIN-1
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 3127
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| 6 mg Orforglipron | n/r | n/r | n/r | n/r |
| 12 mg Orforglipron | n/r | n/r | n/r | n/r |
| 36 mg Orforglipron | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- 6 mg Orforglipron: endpoint not reported
- 12 mg Orforglipron: endpoint not reported
- 36 mg Orforglipron: endpoint not reported